These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15551031)

  • 21. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
    Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
    Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of action of liver contrast agents: impact for clinical use.
    Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
    Rummeny EJ; Peters PE
    Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detection of liver lesions with gadolinium-enhanced VIBE sequence in comparison with SPIO-enhanced MRI].
    Heim P; Steiner P; Schoder V; Dieckmann C; Kuhlencordt R; Adam G
    Rofo; 2003 Oct; 175(10):1376-83. PubMed ID: 14556107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current uses of gadolinium chelates for clinical magnetic resonance imaging examination of the liver.
    Low RN
    Top Magn Reson Imaging; 1998 Jun; 9(3):141-66. PubMed ID: 9621404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New contrast agents for imaging the liver.
    Helmberger T; Semelka RC
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].
    Vogl TJ; Hammerstingl R; Schnell B; Eibl-Eibesfeldt B; Peqios W; Lissner J
    Bildgebung; 1992 Dec; 59(4):195-9. PubMed ID: 1292771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
    Rofsky NM; Earls JP
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver-specific MR imaging contrast agents.
    Hahn PF; Saini S
    Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients.
    Hamm B; Vogl TJ; Branding G; Schnell B; Taupitz M; Wolf KJ; Lissner J
    Radiology; 1992 Jan; 182(1):167-74. PubMed ID: 1309218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions. Initial findings.
    Birnbaum BA; Weinreb JC; Fernandez MP; Brown JJ; Rofsky NM; Young SW
    Clin Imaging; 1994; 18(1):21-7. PubMed ID: 8180855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small (Kim KW; Kim AY; Kim TK; Park SH; Kim HJ; Lee YK; Park MS; Ha HK; Kim PN; Kim JC; Lee MG
    AJR Am J Roentgenol; 2004 May; 182(5):1233-40. PubMed ID: 15100125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uptake of mangafodipir trisodium (MnDPDP) by hepatocellular carcinoma: correlation with unenhanced imaging findings and histopathologic features.
    Chezmar JL; Redvanly RD; Sewell CW
    Acad Radiol; 1996 Aug; 3 Suppl 2():S413-4. PubMed ID: 8796617
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.
    Ba-Ssalamah A; Uffmann M; Saini S; Bastati N; Herold C; Schima W
    Eur Radiol; 2009 Feb; 19(2):342-57. PubMed ID: 18810454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Organ specific MRI contrast media in general practice].
    Schima W
    Wien Med Wochenschr Suppl; 2002; (113):8-11. PubMed ID: 12621828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contrast-enhanced MR imaging of the liver.
    Saini S
    Radiology; 1992 Jan; 182(1):12-4. PubMed ID: 1727273
    [No Abstract]   [Full Text] [Related]  

  • 37. [Focal secondary malignant liver lesions: MnDPDP-enhanced MRT at 0.2 tesla vs. helical CT-arterioportography].
    Rieger J; Körner M; Linsenmaier U; Rock C; Wirth S; Pfeifer KJ
    Rofo; 2002 Nov; 174(11):1402-7. PubMed ID: 12424667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging.
    Federle M; Chezmar J; Rubin DL; Weinreb J; Freeny P; Schmiedl UP; Brown JJ; Borrello JA; Lee JK; Semelka RC; Mattrey R; Dachman AH; Saini S; Harms SE; Mitchell DG; Anderson MW; Halford HH; Bennett WF; Young SW; Rifkin M; Gay SB; Ballerini R; Sherwin PF; Robison RO
    J Magn Reson Imaging; 2000 Nov; 12(5):689-701. PubMed ID: 11050638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimodality diagnosis of liver tumors: feature analysis with CT, liver-specific and contrast-enhanced MR, and a computer model.
    Seltzer SE; Getty DJ; Pickett RM; Swets JA; Sica G; Brown J; Saini S; Mattrey RF; Harmon B; Francis IR; Chezmar J; Schnall MO; Siegelman ES; Ballerini R; Bhat S
    Acad Radiol; 2002 Mar; 9(3):256-69. PubMed ID: 11887942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver lesion detection and characterization with sequential use of hepatobiliary contrast agent mangafodipir trisodium and gadolinium-DTPA in a single imaging protocol.
    Sahani DV; Saini S; Kalra MK; Michael M; Hahn PF
    Acad Radiol; 2002 Aug; 9 Suppl 2():S460-2. PubMed ID: 12188308
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.